How is Kymera doing today?
While information on Kymera’s current revenue is limited, it seems that the company is still doing quite well in terms of sales. The company announced on Instagram that its stock had completely sold out for the summer 2023 season, and it started taking preorders for 2024 stock as early as August of the prior year. The average price target for Kymera Therapeutics, Inc. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months. The highest analyst price target is $72. The average price target represents 58. Increase from the current price of $35.On average, Wall Street analysts predict that Kymera Therapeutics’s share price could reach $57. Mar 13, 2026. The average Kymera Therapeutics stock price prediction forecasts a potential upside of 87. KYMR share price of $30.
Who is the CEO of Kymera?
Founder, President & CEO Nello is Founder, President, and Chief Executive Officer of Kymera Therapeutics. When did Kymera Therapeutics go public? Kymera Therapeutics completed its IPO on August 20, 2020.State of Possible: Kymera Therapeutics Founder and CEO Nello Mainolfi talks protein degradation, his take on recent industry data, and updates on the company’s programs, including a new one to come.